Compugen (CGEN) Q3 2026 Earnings Call Transcript

CGEN reported Q3 2026 revenue of $3.8 million and a net loss of $5.8 million, while ending the quarter with $117.5 million in cash and equivalents. Management says that cash funds operations into 2029, removing near-term financing pressure from the story.

The key catalyst is clinical. CGEN completed enrollment in its MAIA-Ovarian trial for COM701, with data expected by the end of Q1 2027. That sets a defined binary window roughly one quarter after the next earnings cycle.

Partnerships add depth. AZN's rilvegostomig, a CGEN partnered program, is now running in 12 Phase III trials. GILD's GS-0321, another partnered program, continues to advance. Interpretation: the volume of Phase III activity on rilvegostomig suggests CGEN's partner-driven exposure is broader than its own pipeline alone, though the source gives no economics on those arrangements.

CGEN also introduced UnigenX, extending its discovery platform into tumor-associated antigens for T-cell engagers. The source provides no timeline or financial terms for the platform, so treat it as a strategic signal rather than a near-term driver.